How to Choose a Drug Screening Provider for Employment Testing

Key takeaways

• Employment drug screening coordinates specimen collection, chain of custody, laboratory analysis, and Medical Review Officer review when required.
• Employers should choose urine, oral fluid, or hair testing based on the desired detection period, applicable rules, role requirements, cost, and turnaround expectations.
• Provider selection should assess collection-network access, MRO procedures, turnaround times, ATS or API workflows, geographic coverage, and support for state-specific requirements.
• DOT-regulated testing follows federal procedures, while non-DOT programs give employers more discretion within applicable state and local laws.
• Screening providers can support an employer’s compliance processes, but they do not guarantee legal compliance. Employers remain responsible for their policies and hiring decisions.

What drug screening for employment actually involves

Employment drug screening follows a documented path through specimen collection, laboratory analysis, and result verification. A screening provider typically coordinates the test order, candidate instructions, collection location, laboratory processing, and delivery of the final result. Employers may also receive status updates when a candidate schedules or completes the test.

Collection starts when an authorized collector confirms the candidate’s identity and obtains the required specimen. The collector seals and labels the specimen before documenting its transfer to the laboratory. Chain of custody means the documented record showing who collected, handled, transferred, and received a specimen. Complete records help establish that the laboratory tested the correct specimen and that handlers protected it against tampering.

The laboratory first screens the specimen against defined cutoff levels for the substances in the ordered panel. When an initial screen detects a substance above the applicable cutoff, the laboratory performs a more specific confirmation test. A non-negative result means an initial result that requires confirmation and review. A non-negative result does not by itself establish unauthorized drug use.

A Medical Review Officer evaluates laboratory findings before the employer receives a verified result when the testing program requires MRO review. MRO review means an independent physician’s assessment of the laboratory result and any legitimate medical explanation, such as a valid prescription. The MRO may contact the candidate, review supporting information, and report the result under the applicable testing rules. Employers should confirm whether a provider includes MRO review, how the provider handles candidate contact, and which final result categories appear in its reports.

Testing methods: urine, oral fluid, hair, and what each detects

Employers should choose a specimen type based on the period of drug use they need to detect and the collection experience they can accept. Detection windows vary with the substance, frequency of use, test cutoff, specimen quality, and laboratory method. No specimen test can establish current impairment by itself.

Urine testing remains the most common choice for pre-employment screening. Laboratories test urine for drug metabolites that may remain after the immediate effects have ended. Many substances remain detectable for several days, while repeated cannabis use may produce a longer window. Routine collections generally occur in private, although DOT rules require direct observation in certain return-to-duty and follow-up situations. Urine testing usually costs less than hair testing and supports a wide range of panels.

Oral fluid testing focuses on more recent use. A collector watches the candidate provide a saliva sample with a mouth swab, which reduces opportunities for substitution without requiring the privacy intrusion of an observed urine collection. Detection often begins within hours of use and commonly extends through the next day or two, depending on the drug and testing method. Employers often use oral fluid when recent consumption matters, such as post-accident or reasonable-suspicion testing.

For a closer look at how on-site mouth swab tests work, see our guide to saliva drug testing for employers.

Hair testing provides a longer historical view. A laboratory can generally assess about 90 days of use when the collector obtains approximately 1.5 inches of head hair, although the exact period depends on sample length and laboratory procedures. Hair testing may miss very recent use because drugs need time to appear in growing hair. Collection is directly observed and difficult to substitute, but hair testing generally costs more and may take longer than urine or oral fluid testing.

Turnaround depends on whether the specimen produces a negative or non-negative screening result. Some urine and oral fluid options can provide preliminary results quickly. A non-negative specimen requires laboratory confirmation and usually MRO review, which adds time. Buyers should ask each provider for specimen-specific pricing and separate turnaround commitments for negative, confirmed positive, and inconclusive results.

DOT vs. non-DOT testing: why the distinction matters

DOT testing follows a federal protocol for employees in safety-sensitive transportation roles. The applicable DOT agency determines which positions require testing, while 49 CFR Part 40 governs collection and testing procedures. Employers must use the federally specified five-panel test, an HHS-certified laboratory, documented chain-of-custody procedures, and a DOT-qualified Medical Review Officer.

Non-DOT testing covers programs that an employer creates outside DOT requirements. Employers can select the specimen type, testing panel, timing, and circumstances for testing, subject to federal, state, and local law. A non-DOT program may use urine, oral fluid, or hair when applicable, and employers can tailor the panel to workplace risks and legal restrictions. For help matching a panel to each role, see our 10-panel drug test guide.

Employers often make errors when they apply the wrong framework to a position. A non-DOT test cannot replace a required DOT test, even when the non-DOT panel includes similar substances. Conversely, DOT procedures should not automatically govern employees who fall outside a DOT-regulated testing program. Providers can help classify orders and coordinate the required workflow, but they cannot guarantee an employer’s legal compliance.

DOT authorized oral fluid testing in 2023, but employers cannot use that method until HHS certifies at least two laboratories to process the specimens. According to a May 2026 status update, HHS had not certified the required laboratories as of mid-2026. DOT testing therefore remained urine-only at that time. DOT rules do not permit hair testing.

Drug test panels: 5-, 7-, 9-, 10-panel and DOT

A panel count refers to the drug classes screened, not the number of individual substances. VICTIG offers the following options.

Employers should match the panel to job duties, workplace risks, written policies, and applicable state or local rules. A higher panel count does not automatically make a testing program more appropriate.

State and local law variation employers must account for

State and local rules can change which applicants you may test, which methods you may use, and how you may act on a result. Employers should evaluate providers on whether they track requirements by work location, flag policy conflicts, and support required notices or documentation.

Marijuana rules require particular attention. California limits employment decisions based on lawful off-duty cannabis use and tests that detect nonpsychoactive cannabis metabolites, subject to exceptions. New York generally restricts testing for marijuana, though exceptions apply. Other jurisdictions may require advance notice, a written testing policy, or specific testing methods.

Federal and state marijuana rules also differ. In May 2026, the Department of Justice moved FDA-approved and state-licensed medical marijuana to Schedule III, while recreational marijuana remained Schedule I, according to Morgan Lewis guidance published in May 2026. DOT rules remain separate. DOT does not accept state-authorized marijuana use as a valid medical explanation for a positive test.

A provider can identify jurisdictional requirements and configure screening workflows around them. A provider cannot guarantee that an employer’s policy or decision complies with every applicable law. Employers retain legal responsibility and should have employment counsel review their testing policy, especially when hiring across multiple jurisdictions or testing for marijuana.

What separates drug screening provider models

Collection-network breadth determines how easily candidates can complete testing. Employers should assess candidate travel distance, appointment availability, operating hours, and access in rural markets. A large network offers limited value if nearby sites cannot perform the required specimen collection or accommodate expected hiring volume.

Medical Review Officer procedures affect how providers report non-negative laboratory findings. A qualified MRO contacts the candidate when appropriate, reviews valid medical explanations, and verifies the final result before the employer receives it. Buyers should ask who performs the review, how quickly candidate outreach begins, and how unresolved cases appear in the reporting portal.

Turnaround time should reflect each stage of the testing workflow. Providers should distinguish the typical time for a negative result from the longer process required for laboratory confirmation and MRO review. Employers should also ask when the clock starts, how weekends affect timing, and whether the provider reports delays before they disrupt a start date.

Integration depth determines how much manual work remains for recruiters. Basic ATS connections may support test ordering and status updates, while deeper API connections can place screening functions inside an existing hiring workflow. Buyers should confirm which actions the integration supports instead of treating any listed integration as complete automation.

Geographic and state-specific coverage affects whether one program can support hiring across jurisdictions. Providers may help employers identify collection restrictions, required notices, and rules governing marijuana testing. Employers remain responsible for reviewing their policies with qualified counsel because a screening provider can support compliance processes but cannot guarantee legal compliance.

Provider models package these capabilities differently. Standalone drug-testing specialists concentrate on specimen collection, laboratory coordination, and related testing administration. Some specialists focus heavily on regulated programs such as DOT testing. Background screening platforms bundle drug screening with criminal searches, employment verification, and other hiring checks.

VICTIG fits the bundled background screening model. Employers can coordinate drug screening alongside broader pre-employment checks through one provider rather than operating a separate drug-testing relationship. Buyers should compare that convenience against their need for specialized testing administration, network access, integration functions, and jurisdiction-specific support.

Comparing drug screening providers

Provider models differ in how they coordinate collection sites, MRO review, results, hiring software, and jurisdictional requirements. Employers should confirm each capability in writing because service levels vary within every category. Providers can support compliance processes, but they cannot guarantee that an employer’s program meets every applicable law.

Provider-selection checklist for employers

Use the same hiring scenario to evaluate every provider. Include expected testing volume, hiring locations, regulated roles, specimen types, and the background checks you plan to order.

• Collection network. Map collection sites against every location where you hire, including rural areas. Confirm operating hours, appointment requirements, mobile collection options, candidate travel distances, and procedures for missed or delayed collections.
• MRO review. Confirm that a qualified Medical Review Officer reviews non-negative laboratory results and contacts candidates when appropriate. Ask how the provider handles prescriptions, unreachable candidates, result corrections, and employer questions.
• Turnaround time. Request separate estimates for negative results, non-negative results, and tests requiring confirmation. Review when the clock starts, how weekends affect timing, and whether the contract includes service targets or escalation procedures.
• ATS and API workflows. Test the full applicant tracking system workflow before signing. Verify how you order tests, send candidate instructions, monitor status, receive results, control user access, and combine drug screening with other employment checks. If you need an API, request current documentation and confirm which functions the integration supports.
• State coverage. Give each provider a list of the states and cities where you operate. Ask what guidance the provider offers for local notice rules, marijuana restrictions, permitted testing circumstances, required policy language, and changes in applicable requirements.
• Independent legal review. Have employment counsel review your testing policy, consent documents, adverse-action procedures, and jurisdiction-specific practices. A screening provider can support your compliance process and flag potential requirements, but it cannot guarantee that your program complies with every applicable law.

Before committing, run a pilot with representative locations and roles. Document any collection delays, integration problems, candidate complaints, and support response times, then compare the results with the provider’s contract terms.

Where VICTIG fits for employers coordinating drug screening and background checks

VICTIG operates as a background screening provider that coordinates drug testing alongside criminal searches, employment verification, and other hiring checks. Employers can manage related screening services through one provider instead of arranging drug tests separately from the broader background-check process.

VICTIG supports ATS integrations and a documented API/XML Gateway for exchanging screening information with other systems. Public information does not confirm specific API architecture or implementation features beyond its API/XML capabilities, so employers should verify technical requirements during evaluation. VICTIG reports a 1.8-day average turnaround time across its screening services, but drug test timing can vary based on specimen type, collection scheduling, laboratory processing, and MRO review.

VICTIG may fit employers that want coordinated screening workflows and direct customer support. Employers focused solely on drug testing may prefer a specialized laboratory, collection network, or DOT program administrator. In either model, the provider supports collection and compliance processes but cannot guarantee legal compliance. Employers remain responsible for their testing policies, hiring decisions, and applicable federal, state, and local requirements.

Frequently asked questions

• When does an employer need DOT testing instead of non-DOT testing? DOT testing applies when federal transportation rules cover the employee’s safety-sensitive position. Employers generally use non-DOT testing for positions outside those rules. Job duties and the governing federal agency determine which framework applies.
• How long does a pre-employment drug test take? Collection method, laboratory workload, specimen transport, and MRO review affect turnaround. Negative results often return faster than non-negative results because an MRO may need to contact the candidate and review prescription information. Employers should request separate turnaround estimates for routine and non-negative results.
• What does an MRO review change about a drug test result? A Medical Review Officer reviews laboratory findings and determines whether a legitimate medical explanation accounts for a non-negative result. For example, the MRO may verify a result as negative when a valid prescription explains the detected substance. The MRO also protects medical details that the employer does not need to receive.
• Can employers test for marijuana? Employers may test for marijuana when applicable law permits it, but state and local rules can restrict testing or employment decisions involving off-duty use. DOT rules remain stricter, and state-authorized marijuana use does not provide a valid medical explanation for a positive DOT result. Employers should review current policies with employment counsel because marijuana laws and federal treatment continue to change.
• Does a drug screening provider make an employer legally compliant? No. A provider can coordinate collections, laboratory testing, MRO review, documentation, and jurisdiction-specific workflows. The employer remains responsible for its policy, notices, test timing, employment decisions, and legal review.

Conclusion

Employers should choose a drug screening provider through a structured review of collection access, MRO procedures, turnaround expectations, hiring-system integrations, and support for relevant jurisdictions. Contract terms and service claims should match the employer’s actual roles, locations, and testing policies.

Screening providers can support compliance processes, but no provider can guarantee that an employer complies with every applicable law. Employers remain responsible for program design, hiring decisions, and legal review with qualified counsel. A criteria-based evaluation serves employers that hire across multiple states, operate in regulated industries, or need to coordinate drug screening with broader background checks.